- Home
- IMCR vs STAA Comparison
IMCR vs STAA Comparison
Compare IMCR & STAA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- STAA
- Stock Information
- Founded
- IMCR 2008
- STAA 1982
- Country
- IMCR United Kingdom
- STAA United States
- Employees
- IMCR N/A
- STAA N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- STAA Ophthalmic Goods
- Sector
- IMCR Health Care
- STAA Health Care
- Exchange
- IMCR Nasdaq
- STAA Nasdaq
- Market Cap
- IMCR 1.7B
- STAA 1.4B
- IPO Year
- IMCR 2021
- STAA N/A
- Fundamental
- Price
- IMCR $31.60
- STAA $26.98
- Analyst Decision
- IMCR Buy
- STAA Hold
- Analyst Count
- IMCR 9
- STAA 8
- Target Price
- IMCR $62.38
- STAA $22.50
- AVG Volume (30 Days)
- IMCR 358.7K
- STAA 1.2M
- Earning Date
- IMCR 11-06-2025
- STAA 11-06-2025
- Dividend Yield
- IMCR N/A
- STAA N/A
- EPS Growth
- IMCR N/A
- STAA N/A
- EPS
- IMCR N/A
- STAA N/A
- Revenue
- IMCR $356,145,000.00
- STAA $224,449,000.00
- Revenue This Year
- IMCR $29.99
- STAA N/A
- Revenue Next Year
- IMCR $8.85
- STAA $27.24
- P/E Ratio
- IMCR N/A
- STAA N/A
- Revenue Growth
- IMCR 26.78
- STAA N/A
- 52 Week Low
- IMCR $23.15
- STAA $13.50
- 52 Week High
- IMCR $39.33
- STAA $32.00
- Technical
- Relative Strength Index (RSI)
- IMCR 39.83
- STAA 54.61
- Support Level
- IMCR $31.52
- STAA $23.88
- Resistance Level
- IMCR $34.11
- STAA $26.78
- Average True Range (ATR)
- IMCR 1.33
- STAA 1.24
- MACD
- IMCR -0.16
- STAA -0.03
- Stochastic Oscillator
- IMCR 8.78
- STAA 94.93
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About STAA STAAR Surgical Company
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company also makes lenses that are used in surgery to treat cataracts. The company offers two types of products: Implantable Collamer lenses (ICL) and intraocular lens (IOL). The ICLs are used in refractive surgery and IOLs are used in cataract surgery. The majority of its sales are generated from the ophthalmic surgical product segment.